sellModerate
Weiss Asset Management LP sold $233M of AVDL
other at AVADEL PHARMACEUTICALS PLC. 11,112,052 shares at an average of $21.00, traded Feb 13, 2026, filed Feb 18, 2026.
Warning score
53Value
$233M
11,112,052 shares
Holdings after
0
-100% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +8RoleOther
- +25Trade size$233.4M at market
- +20Share of holdings soldSold 100% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001357550-26-000015, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 13, 2026 | SOpen-market sale Ordinary Sharesindirect: See Footnote 2 | -11,112,052 | $21.00 | $233M | 0 | Feb 18, 2026 |
Related signals
Other insiders at AVADEL PHARMACEUTICALS PLC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 44Moderate | AVADEL PHARMACEUTICALS PLC | Linda Palczuk director | $40k 5,000 shares | +8% | |
| 46Moderate | AVADEL PHARMACEUTICALS PLC | Eric J Ende director | $235k 30,000 shares | +17% | |
| 42Moderate | AVADEL PHARMACEUTICALS PLC | Peter J. Thornton director | $80k 10,000 shares | +11% | |
| 42Moderate | AVADEL PHARMACEUTICALS PLC | Thomas S McHugh Chief Financial Officer | $24k 2,300 shares | +3% | |
| 47Moderate | AVADEL PHARMACEUTICALS PLC | Thomas S McHugh Chief Financial Officer | $52k 5,000 shares | +6% | |
| 35Weak | AVADEL PHARMACEUTICALS PLC | Linda Palczuk director | $31k 3,000 shares | +5% | |
| 48Moderate | AVADEL PHARMACEUTICALS PLC | Geoffrey Michael Glass director | $200k 20,279 shares | +34% | |
| 58Moderate | AVADEL PHARMACEUTICALS PLC | Gregory J Divis Chief Executive Officer | $100k 10,000 shares | - | |
| 27Weak | AVDLbuy AVADEL PHARMACEUTICALS PLC | Thomas S McHugh Chief Financial Officer | $29k 2,000 shares | +3% | |
| 40Moderate | AVADEL PHARMACEUTICALS PLC | Mark Anthony McCamish director | $1.1M 75,000 shares | -53% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.